In this study, we found that mutations in CCT5 are most common in LUSC (> 10%), followed by Esophageal Adenocarcinoma (EAC), Bladder Urothelial Carcinoma (BLCA), and Lung Adenocarcinoma (LUAD), which cumulatively indicates that CCT5 mutations influence cancer progression in different tissues. The gene discussed is CCT5; the disease is bladder transitional cell carcinoma.